TPMT status determination: The simplest is the most effective?

Journal of Crohn's and Colitis

Volumn 6, Issue 7, 2012, Pages 807-

  Chouchana, Laurent ^a   Narjoz, Celine ^a   Loriot, Marie Anne ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

BONE MARROW SUPPRESSION; DRUG INDICATION; ENTERITIS; ENZYME ACTIVITY; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LETTER; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; STANDARDIZATION;

6-MERCAPTOPURINE; AZATHIOPRINE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; METHYLTRANSFERASES; PHENOTYPE;

EID: 84863432324     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.04.003     Document Type: Letter

References (5)

1. Hindorf U., Appell M.L. Genotyping should be considered the primary choice for pre-treatment evaluation of thiopurine methyltransferase function. J Crohns Colitis Dec 13 2011, [Epub ahead of print].
2. Relling M.V., Gardner E.E., Sandborn W.J., Schmiegelow K., Pui C.H., Yee S.W., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011, 89:387-391.
3. Yates C.R., Krynetski E.Y., Loennechen T., Fessing M.Y., Tai H.L., Pui C.H., et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997, 126:608-614. [70].
4. Lennard L., Lilleyman J.S., Van Loon J., Weinshilboum R.M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990, 336:225-229.
5. Chouchana L., Roche D., Narjoz C., Pineau B., Chatellier G., Beaune P.H., et al. Gastroenterology 2011, 140:S281-S282.